Baloxavir Marboxil
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Baloxavir Marboxil
- Baloxavir marboxil: From Influenza to Acquired HLH Associated with Malignant Disease
Baloxavir marboxil: From Influenza to Acquired HLH Associated with Malignant Disease
One-Sentence Summary
Baloxavir marboxil is a novel cap-snatching endonuclease (CEN) inhibitor originally developed for the treatment of acute influenza in adults and adolescents. The TxGNN model predicts it may be effective for Acquired Hemophagocytic Lymphohistiocytosis (HLH) Associated with Malignant Disease, however, this remains a model-only prediction (L5) with no supporting clinical trials or literature currently identified for this specific indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acute influenza (cap-snatching endonuclease inhibitor / antiviral) |
| Predicted New Indication | Acquired Hemophagocytic Lymphohistiocytosis Associated with Malignant Disease |
| TxGNN Prediction Score | 98.85% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the system. Based on contextual information embedded in the evidence pack, Baloxavir marboxil functions as a cap-snatching endonuclease (CEN) inhibitor, selectively targeting the PA subunit of the influenza RNA-dependent RNA polymerase complex. By blocking the CEN domain, it prevents the influenza virus from cleaving host cell mRNA to generate primers for viral mRNA synthesis — a mechanism entirely specific to influenza viral replication and structurally unrelated to host immune pathways.
The predicted indication, malignancy-associated HLH, is a life-threatening hyperinflammatory syndrome driven primarily by tumor-mediated immune evasion, uncontrolled macrophage activation, and a cytokine storm (interferon-γ, IL-6, IL-18). This pathophysiology has no established dependency on viral polymerase activity. Unlike infection-triggered HLH — where reducing viral load could theoretically dampen persistent immune activation — malignancy-driven HLH does not involve active viral replication as a primary trigger. Baloxavir’s CEN inhibition therefore has no recognized molecular target in this disease context.
The high TxGNN score (98.85%) most likely reflects a knowledge graph topology artifact: the HLH disease node shares graph edges with influenza-associated HLH, causing the model to elevate Baloxavir’s ranking despite the absence of a direct pharmacological rationale. This pattern — where a disease concept shares a network neighborhood with an antiviral’s known pathology — is a recognized source of false positives in graph-based drug repurposing models, and should not be interpreted as clinical plausibility.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Malignancy-associated HLH is mechanistically disconnected from Baloxavir’s antiviral target (influenza PA-CEN); the unusually high TxGNN prediction score is attributed to a knowledge graph topology artifact — shared network proximity between influenza-related HLH and malignancy-related HLH nodes — rather than genuine pharmacological plausibility.
To proceed, the following is needed:
- Obtain complete drug label and safety data (EMA SmPC or equivalent regulatory dossier) to resolve current data gaps
- Retrieve DrugBank mechanism of action data for Baloxavir marboxil (DB13997) via DrugBank API
- Conduct a targeted case-report literature search for Baloxavir use in influenza-associated HLH specifically, which carries greater biological plausibility than the malignancy-associated subtype
- Consider re-prioritizing the evaluation to Rank 2 (hemophagocytic syndrome associated with an infection) or Rank 5 (hemophagocytic syndrome, general), both of which carry a “Research Question” recommendation and a mechanistically defensible rationale — influenza is a recognized HLH trigger, and antiviral-mediated viral load reduction could theoretically attenuate immune hyperactivation
- If the infection-associated HLH angle is pursued further, a systematic review of influenza-associated HLH outcomes and any case reports of antiviral intervention would be the minimum evidence threshold before advancing to hypothesis generation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.